Maynard Um
-
-
-
-
-
-
-
Eisai, Biogen launch subcutaneous Leqembi autoinjector in the U.S.
-
-
-
-
-
-
-
Guggenheim Reiterates Buy Rating on Biogen (BIIB)
-
-
-
-
-
-
-
Piper Sandler Reiterates Overweight Rating on Biogen (BIIB)
-
-
-
-
-
-
-
Needham Reiterates Buy Rating on Biogen (BIIB)
-
-
-
-
-
-
-
Biogen (BIIB) PT Raised to $300 at Oppenheimer
-
-
-
-
-
-
-
Freedom Broker Upgrades Biogen (BIIB) to Buy, raises PT to $245
-
-
-
-
-
-
-
Biogen (BIIB) PT Raised to $203 at BofA Securities
-
445,664 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

